35.34
Precedente Chiudi:
$34.61
Aprire:
$35.09
Volume 24 ore:
193.51K
Relative Volume:
0.28
Capitalizzazione di mercato:
$1.85B
Reddito:
$1.24B
Utile/perdita netta:
$23.68M
Rapporto P/E:
84.15
EPS:
0.42
Flusso di cassa netto:
$108.67M
1 W Prestazione:
+1.57%
1M Prestazione:
-10.47%
6M Prestazione:
-33.72%
1 anno Prestazione:
-34.55%
Livanova Plc Stock (LIVN) Company Profile
Nome
Livanova Plc
Settore
Industria
Telefono
4402033250662
Indirizzo
20 EASTBOURNE TERRACE, LONDON
Confronta LIVN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
LIVN
Livanova Plc
|
35.33 | 1.85B | 1.24B | 23.68M | 108.67M | 0.42 |
![]()
ABT
Abbott Laboratories
|
131.57 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
94.82 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
347.57 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
83.37 | 106.51B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
70.47 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2024-10-04 | Iniziato | Goldman | Buy |
2024-09-17 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2024-03-20 | Reiterato | Needham | Buy |
2024-02-20 | Aggiornamento | Mizuho | Neutral → Buy |
2023-09-06 | Iniziato | HSBC Securities | Hold |
2023-07-19 | Iniziato | Robert W. Baird | Neutral |
2023-04-14 | Iniziato | Mizuho | Neutral |
2022-12-21 | Iniziato | Barclays | Equal Weight |
2022-04-06 | Iniziato | Wolfe Research | Outperform |
2022-02-24 | Aggiornamento | UBS | Neutral → Buy |
2021-12-03 | Iniziato | Goldman | Buy |
2021-08-20 | Reiterato | Needham | Buy |
2021-07-20 | Aggiornamento | Needham | Hold → Buy |
2021-03-03 | Downgrade | Berenberg | Buy → Hold |
2021-01-05 | Downgrade | Needham | Buy → Hold |
2020-09-02 | Iniziato | Robert W. Baird | Outperform |
2020-06-26 | Reiterato | Needham | Buy |
2019-10-30 | Reiterato | Needham | Buy |
2019-02-28 | Reiterato | Needham | Buy |
2018-11-28 | Iniziato | UBS | Neutral |
2018-08-02 | Reiterato | Needham | Buy |
2018-06-08 | Iniziato | Stifel | Buy |
2018-05-31 | Reiterato | Needham | Buy |
2018-02-28 | Reiterato | Needham | Buy |
Mostra tutto
Livanova Plc Borsa (LIVN) Ultime notizie
Mizuho Adjusts Price Target for LivaNova (LIVN) Ahead of Q1 Preview | LIVN Stock News - GuruFocus
What Is LivaNova PLC's (NASDAQ:LIVN) Share Price Doing? - Yahoo Finance
LivaNova PLC (LIVN): Among the Best UK Stocks to Buy According to Billionaires - Insider Monkey
Cardiovascular Devices Market Demand, Growth and Future Scope - openPR.com
Vagus Nerve Stimulators Market Deep Research Report with - openPR.com
With LivaNova PLC (NASDAQ:LIVN) It Looks Like You'll Get What You Pay For - simplywall.st
Aortic Stenosis Market to Witness Massive Growth by 2032 | - openPR.com
10 Best UK Stocks to Buy According to Billionaires - Insider Monkey
LivaNova PLC: Excellent Revenue Earner, Some Short-Term Litigation Concerns (LIVN) - Seeking Alpha
LivaNova stock plunges to 52-week low, touches $36.18 By Investing.com - Investing.com Canada
LivaNova stock plunges to 52-week low, touches $36.18 - Investing.com Australia
Vagus Nerve Stimulators Market Size, Growth Trends and Report - openPR.com
(LIVN) Trading Advice - news.stocktradersdaily.com
LivaNova PLC (NASDAQ:LIVN) Shares Bought by Prudential Financial Inc. - MarketBeat
Implantable Cardioverter Defibrillators Market to Witness - openPR.com
LivaNova (NASDAQ:LIVN) Upgraded at StockNews.com - MarketBeat
LivaNova to Announce First-Quarter 2025 Results - Sharewise
LivaNova (NASDAQ:LIVN) investors are sitting on a loss of 50% if they invested three years ago - Yahoo Finance
Should You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now? - simplywall.st
LivaNova PLC (LIVN) Shares Up 0.4% on Mar 19 - GuruFocus.com
Vagus Nerve Stimulators Market is Expected to Witness Positive Growth With A CAGR of 9.06% by 2030, estimates DelveInsight - The Globe and Mail
Vagus Nerve Stimulators Market is Expected to Witness Positive - openPR
Jefferies cuts Livanova stock price target to $74 from $80 - Investing.com India
Barclays maintains Livanova stock with $56 target, cites clarity By Investing.com - Investing.com South Africa
Jefferies cuts Livanova stock price target to $74 from $80 By Investing.com - Investing.com Australia
LivaNova to record $363 million liability after court ruling By Investing.com - Investing.com Australia
Needham maintains Livanova buy rating, $64 target amid liability By Investing.com - Investing.com Australia
Barclays Maintains Livanova (LIVN) at Equalweight - StreetInsider.com
Barclays Starts Livanova (LIVN) at Equalweight - StreetInsider
Needham maintains Livanova buy rating, $64 target amid liability - Investing.com
LivaNova to record $363 million liability after court ruling - Investing.com
LivaNova Faces €333 Million Liability Ruling - TipRanks
Supreme Court Rules LivaNova Not Liable For 157 Mln Euros Payments In Environmental Liabilities Case - Marketscreener.com
LivaNova PLC (NASDAQ:LIVN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
LivaNova’s SWOT analysis: medical tech firm’s stock faces growth and legal hurdles - Investing.com Australia
Cardiovascular Devices Market Booming with Technological - openPR
Autotransfusion Devices and Consumables Market is Estimated - openPR
LivaNova’s SWOT analysis: medical tech firm’s stock faces growth and legal hurdles By Investing.com - Investing.com South Africa
LivaNova PLC (NASDAQ:LIVN) Shares Sold by Bank of New York Mellon Corp - Defense World
Vagus Nerve Stimulators Market Generated Opportunities, - openPR
LivaNova at Barclays Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
LivaNova at Barclays Conference: Strategic Growth and Innovation - Investing.com India
When the Price of (LIVN) Talks, People Listen - Stock Traders Daily
Goldman Sachs maintains Livanova buy rating, $55 target By Investing.com - Investing.com UK
Livanova Plc Azioni (LIVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Livanova Plc Azioni (LIVN) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Makatsaria Vladimir | Chief Executive Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
9,330 |
0 |
9,330 |
KOZY WILLIAM A | Director |
Mar 30 '25 |
Option Exercise |
0.00 |
1,034 |
0 |
28,496 |
Hutchinson Michael Damon | Chief Legal Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
2,930 |
0 |
6,686 |
Shvartsburg Alex | Chief Financial Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
11,083 |
0 |
30,196 |
Poletti Franco | President, Cardiopulmonary |
Mar 30 '25 |
Option Exercise |
0.00 |
1,257 |
0 |
8,475 |
Hutchinson Michael Damon | Chief Legal Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
2,254 |
0 |
4,540 |
Poletti Franco | President, Cardiopulmonary |
Dec 15 '24 |
Option Exercise |
0.00 |
967 |
0 |
7,634 |
Barry James Christopher | Director |
Dec 15 '24 |
Option Exercise |
0.00 |
1,709 |
0 |
1,709 |
Shvartsburg Alex | Chief Financial Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
613 |
0 |
19,342 |
Bianchi Francesco | Director |
Dec 11 '24 |
Sale |
50.99 |
1,250 |
63,738 |
7,522 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):